Post hoc analysis of use of proteomic aging clocks to predict risk of mortality among long-term cancer survivors

Researchers at the University of Minnesota (Minneapolis) developed a proteomic aging clock in cancer-free participants and examined its association with mortality among long-term (> 2 years) cancer survivors in the prospective ARIC and MESA studies. Increased biologic aging was associated with increased all-cause mortality both in ARIC and in MESA. In ARIC, increased biologic aging was associated with all-cause mortality in survivors of breast and colorectal cancers, and with cancer-specific mortality. The authors conclude that proteomic aging clocks hold promise as predictors of all-cause and cancer mortality in long-term cancer survivors.